Unity Biotechnology, a preclinical biotech developing therapies for aging-related diseases, filed on Thursday with the SEC to raise up to $85 million in an initial public offering.
The Brisbane, CA-based company was founded in 2009 and booked $1 million in sales for the 12 months ended December 31, 2017. It plans to list on the Nasdaq under the symbol UBX. Goldman Sachs, Morgan Stanley and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
